Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Acinar Cell
/ drug therapy
Deoxycytidine
/ administration & dosage
Female
Fluorouracil
/ administration & dosage
Humans
Irinotecan
/ administration & dosage
Kaplan-Meier Estimate
Leucovorin
/ administration & dosage
Male
Middle Aged
Neoplasm Metastasis
Oxaliplatin
/ administration & dosage
Pancreas
/ drug effects
Pancreatic Neoplasms
/ drug therapy
Retrospective Studies
Gemcitabine
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
1
1
2022
Statut:
ppublish
Résumé
Acinar cell carcinoma of the pancreas (pACC) forms a rare subgroup of pancreatic tumors. We report on our institutional experience with systemic first- and further-line therapy in patients with metastatic pACC and embed our findings in a review of the literature. Patients with stage IV pACC who started systemic treatment between 2008 and 2019 at our institution were identified via our institutional database. Clinical data were extracted from the patients' electronic data records. Survival times were calculated by the Kaplan-Meier method. Six patients received a fluoropyrimidine- and oxaliplatin-containing first-line treatment, and 4 patients were started on gemcitabine-based protocols. Median progression-free survival was 4.8 months [95% confidence interval (CI), 3.3 to not available (n.a.)], and median overall survival was 15.3 months (95% CI, 10.1 to n.a.). Residual survival for second-line treatment was 2.1 months (95% CI, 1.3 to n.a.), although 1 patient experienced almost complete remission under targeted therapy. The most encouraging and deep responses result from poly-chemotherapy with leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), which seems to be the appropriate choice in fit patients. Gemcitabine monotherapy seems without substantial activity in pACC. Whenever possible, patients with pACC should be screened for targetable mutations.
Identifiants
pubmed: 33835959
doi: 10.1097/MPA.0000000000001765
pii: 00006676-202103000-00004
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Deoxycytidine
0W860991D6
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Gemcitabine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
300-305Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery . 2008;144:141–148.
Schmidt CM, Matos JM, Bentrem DJ, et al. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg . 2008;12:2078–2086.
Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol . 1992;16:815–837.
Stelow EB, Shaco-Levy R, Bao F, et al. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol . 2010;34:510–518.
Al-Hader A, Al-Rohil RN, Han H, et al. Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors. World J Gastroenterol . 2017;23:7945–7951.
Kruger S, Haas M, Burger PJ, et al. Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. J Cancer Res Clin Oncol . 2016;142:2585–2591.
Brunetti O, Aprile G, Marchetti P, et al. Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis. Pancreas . 2018;47:759–771.
Yoo C, Kim BJ, Kim KP, et al. Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen. Cancer Res Treat . 2017;49:759–765.
Busch E, Kreutzfeldt S, Agaimy A, et al. Successful BRAF/MEK inhibition in a patient with BRAFV600E -mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud . 2020;6:a005553.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol . 1982;5:649–655.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45:228–247.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med . 2011;364:1817–1825.
Furukawa T, Sakamoto H, Takeuchi S, et al. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep . 2015;5:8829.
Seki Y, Okusaka T, Ikeda M, et al. Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. Jpn J Clin Oncol . 2009;39:751–755.
Béchade D, Desjardin M, Salmon E, et al. Pancreatic acinar cell carcinoma. Case Rep Gastroenterol . 2016;10:174–180.
Kaur S, Morris D, Ho G, et al. An unusual case of primary acinar cell carcinoma of the liver and its treatment. J Gastrointest Oncol . 2019;10:1021–1026.
Ploquin A, Baldini C, Vuagnat P, et al. Prolonged survival in a patient with a pancreatic acinar cell carcinoma. Case Rep Oncol . 2015;8:447–450.
Armstrong MD, Von Hoff D, Barber B, et al. An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. J Cancer . 2011;2:142–152.
Cananzi FC, Jayanth A, Lorenzi B, et al. “Chronic” metastatic pancreatic acinar cell carcinoma. Pancreatology . 2013;13:549–552.
Yoshida N, Kanno A, Masamune A, et al. Pancreatic acinar cell carcinoma with multiple liver metastases effectively treated by S-1 chemotherapy. Intern Med . 2018;57:3529–3535.
Yamamoto T, Ohzato H, Fukunaga M, et al. Acinar cell carcinoma of the pancreas: a possible role of S-1 as chemotherapy for acinar cell carcinoma. A case report. JOP . 2012;13:87–90.
Callata-Carhuapoma HR, Pato Cour E, Garcia-Paredes B, et al. Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. Pancreatology . 2015;15:440–444.
Hashimoto M, Hikichi T, Suzuki T, et al. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. Clin J Gastroenterol . 2017;10:564–569.
Schempf U, Sipos B, König C, et al. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Z Gastroenterol . 2014;52:200–203.
Yoshihiro T, Nio K, Tsuchihashi K, et al. Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: a case report. Mol Clin Oncol . 2017;6:866–870.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol . 2007;25:1960–1966.
Horak P, Klink B, Heining C, et al. Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer . 2017;141:877–886.
Bergmann F, Aulmann S, Sipos B, et al. Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Arch . 2014;465:661–672.
Chmielecki J, Hutchinson KE, Frampton GM, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov . 2014;4:1398–1405.